|
(S)-2-Amino-3-(4h-Selenolo[3,2-B]-Pyrrol-6-Yl)-Propionic Acid
|
DB03513 |
|
|
2-Methoxy-4-Vinyl-Phenol
|
DB03514 |
|
|
Tetrabenazine
|
DB04844 |
[A drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders. It is a monoamine depletor and used as symptomatic treatment of chorea associated with Huntington's disease. FDA approved on August 15, 2008.] |
|
Mepenzolate
|
DB04843 |
[Mepenzolate is a post-ganglionic parasympathetic inhibitor. It decreases gastric acid and pepsin secretion and suppresses spontaneous contractions of the colon. Mepenzolate diminishes gastric acid and pepsin secretion. Mepenzolate also suppresses spontaneous contractions of the colon. Pharmacologically, it is a post-ganglionic parasympathetic inhibitor. It has not been shown to be effective in contributing to the healing of peptic ulcer, decreasing the rate of recurrence, or preventing complications.] |
|
alpha-D-galacturonic acid
|
DB03511 |
[The α-anomer of D-galacturonic acid.] |
|
Uridine-2',3'-vanadate
|
DB03512 |
|
|
Fluspirilene
|
DB04842 |
[A long-acting injectable antipsychotic agent used for chronic schizophrenia.] |
|
Flunarizine
|
DB04841 |
[Flunarizine is a selective calcium entry blocker with calmodulin binding properties and histamine H1 blocking activity. It is effective in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and peripheral origin, and as an adjuvant in the therapy of epilepsy.] |
|
6-O-Phosphoryl Inosine Monophosphate
|
DB03510 |
|
|
Debrisoquine
|
DB04840 |
[An adrenergic neuron-blocking drug similar in effects to guanethidine. It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme. Persons with certain isoforms of this enzyme are unable to properly metabolize this and many other clinically important drugs. They are commonly referred to as having a debrisoquin 4-hydroxylase polymorphism.] |
|
Methapyrilene
|
DB04819 |
[Methapyrilene, formerly marketed in many drug products, was shown to be a potent carcinogen. Manufacturers voluntarily withdrew methapyriline drug products from the market in May and June 1979.] |
|
Iproniazid
|
DB04818 |
[Withdrawn from the Canadian market in July 1964 due to interactions with food products containing tyrosine.] |
|
Metamizole
|
DB04817 |
[Metamizole, formerly marketed as Dimethone tablets and injection, Protemp oral liquid, and other drug products, was associated with potentially fatal agranulocytosis. Approvals of the NDA's for dipyrone drug products were withdrawn on June 27, 1977 (see the Federal Register of June 17, 1977 (42 FR 30893)). Withdrawn from the Canadian market in 1963.] |
|
Dantron
|
DB04816 |
[Withdrawn from the Canadian, US, and UK markets in 1998 due to genotoxicity.] |
|
Clioquinol
|
DB04815 |
[Clioquinol was withdrawn in 1983 due to neurotoxicity.] |
|
Bunamiodyl
|
DB04814 |
[Withdrawn from the Canadian, US, and UK markets in 1963 due to nephropathy.] |
|
Bithionol
|
DB04813 |
[Bithionol, formerly marketed as an active ingredient in various topical drug products, was shown to be a potent photosensitizer with the potential to cause serious skin disorders. Approvals of the NDA's for bithionol drug products were withdrawn on October 24, 1967 (see the Federal Register of October 31, 1967 (32 FR 15046)).] |
|
Benoxaprofen
|
DB04812 |
[The use of benoxaprofen, formerly marketed as Oraflex tablets, was associated with fatal cholestatic jaundice among other serious adverse reactions. The holder of the approved application voluntarily withdrew Oraflex tablets from the market on August 5, 1982.] |
|
Salophen iron chelate
|
DB04811 |
|
|
Salophen-10-carboxylate iron chelate
|
DB04810 |
|
